Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
52 participants
INTERVENTIONAL
2019-12-24
2023-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study on the Verification of Kidney CT Non-inferiority Using Low Concentration Contrast Agent
NCT05831943
Early Screening and Diagnosis of CKD
NCT02841371
Development of Early Diagnostic Techniques and Setup of Local Therapeutic Guidelines and Standards
NCT00912704
Applications of MRI in Kidney Disease
NCT02832505
Effect of Ambulatory BP Monitoring on the CliniCal coUrse and RenAl ouTcomE of CKD
NCT02417571
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Low dose
Low CT contrast media dose
low dose CT contrast media
CT contrast media (Ioversol 320mgI/kg) is administrated at a dose of 300mgI/kg in low dose group
Standard dose
Standard CT contrast media dose
Standard dose CT contrast media
CT contrast media (Ioversol 350mgI/kg) is administrated at a dose of 525mgI/kg in standard dose group.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
low dose CT contrast media
CT contrast media (Ioversol 320mgI/kg) is administrated at a dose of 300mgI/kg in low dose group
Standard dose CT contrast media
CT contrast media (Ioversol 350mgI/kg) is administrated at a dose of 525mgI/kg in standard dose group.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Scheduled contrast-enhanced CT for HCC diagnosis or surveillance
* chronic kidney disease (Estimated GFR \< 60mL/min/1.73m2)
Exclusion Criteria
* congestive hepatopathy
* on dialysis
* no venous access on forearm
* anticipated beam hardening artifact due to prosthesis
* relative/absolute contra-indication of contrast-enhanced CT except CKD (Estimated GFR \< 60mL/min/1.73m2)
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seoul National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jeong Min Lee
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jeong Min Lee, MD
Role: PRINCIPAL_INVESTIGATOR
Seoul National University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Yoon JH, Park JY, Lee SM, Lee ES, Kim JH, Lee JM. Renal protection CT protocol using low-dose and low-concentration iodine contrast medium in at-risk patients of HCC and with chronic kidney disease: a randomized controlled non-inferiority trial. Cancer Imaging. 2023 Oct 19;23(1):100. doi: 10.1186/s40644-023-00616-0.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SNUH-2019-0343
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.